A New Drug on the Horizon for HER2 Breast Cancer Patients | Avise Analytics
Puma Biotech's (PBYI) Breast Cancer Drug Nerlynx Aids Growth
Why Puma Biotechnology's Shares Jumped 20% on Monday | The Motley Fool
Puma Biotechnology: Who Are They? What Happened? And, Where Are They Going? (NASDAQ:PBYI) | Seeking Alpha
Jon Mead - Vice President of FP&A - Puma Biotechnology, Inc. | LinkedIn
Puma Biotech punts near $300 million on Takeda discard
Puma Biotechnology: Risky Investment (NASDAQ:PBYI) | Seeking Alpha
ADAPTING
Neratinib Chapter
Puma Biotech (PBYI) Q4 Loss Wider Than Expected, Sales Top | Nasdaq
Neratinib Chapter
Puma Biotechnology
Puma Biotech (PBYI) Q4 Loss Wider Than Expected, Sales Top
PUMA BIOTECHNOLOGY, INC. FORM 10-K - Biotech Due Diligence
Workable Strategic Report on Breast Cancer Therapeutics Drugs
Puma Biotech (PBYI) Q3 Earnings Top, Nerlynx Sales View Up
Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
Why Puma Biotechnology (PBYI) Stock Is Surging Today - TheStreet
PUMA BIOTECHNOLOGY, INC. FORM 8-K/A - Shareholder.com
Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results | Business Wire
Product Pipeline
Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology: Risky Investment (NASDAQ:PBYI) | Seeking Alpha
Puma Biotech Surges, Defying Yellen
Puma Biotech's (PBYI) Nerlynx Aids Top Line, Overdependence a Woe | Nasdaq
